Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Chemokine Therapeutics Corp. announced that Dr. Andrew Zhu has joined the Company's oncology Clinical Advisory Board. The Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.
Dr. Andrew Zhu is an attending oncologist as well as the director of Liver Cancer Research at Massachusetts General Hospital Cancer Center. He is also a staff physician at Dana-Farber Cancer Institute, and a member of Dana-Farber Harvard Cancer Center in Boston, Massachusetts. Dr. Zhu is an assistant professor of medicine at Harvard Medical School and is board-certified in internal medicine and medical oncology, and holds clinical research interests in developing novel treatments for gastrointestinal cancers including hepatocellular carcinoma, bile duct tumor and colorectal cancer.
Dr. Zhu earned his medical degree from Beijing Medical University in Beijing, China. He went on to study microbiology and obtain his Ph.D. at Columbia University in New York City, New York. Dr. Zhu finished his residency at Yale-New Haven Hospital, Yale School of Medicine in New Haven Connecticut and his fellowship in medical oncology and hematology at the Memorial Sloan-Kettering Cancer Center in New York City, Center, New York.
Other news from the department people
